Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

Other illness

• Patients with severe heart, lung, liver, kidney, or other organ dysfunction that may restrict their participation in this trial due to diseases;
• Evidence of other clinically significant uncontrolled condition(s) such as uncontrolled and/or active systemic infection (viral, bacterial or fungal)
• A history of other malignant tumors within the past 5 years, excluding localized thyroid cancer and in situ skin cancer;
• Known HIV infection;
• Gastrointestinal diseases known to affect venetoclax absorption as judged by the investigator;

Lab values

• Serum total bilirubin \>1.5 ULN (upper limit of normal) (excluding leukemia infiltration); ALT or AST or ALP \>5 ULN; serum creatinine \>1.5 ULN and creatinine clearance rate \<40 mL/min; LVEF \<50%;

Other

• Patients who are unable to take venetoclax by mouth;
• Known central nervous system leukemia infiltration;
• Inability to understand or comply with the study protocol.

• Age ≥14 and \<75 years old.
• Diagnosed with ETP-ALL (including near-ETP ALL) before enrollment.
• Newly diagnosed patients.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Expected survival of ≥3 months.
• Able to undergo oral treatment with venetoclax.
• No organ dysfunction that would restrict the treatment administered
• Understanding of the study and signing of the informed consent form.
• Men, women of childbearing potential (postmenopausal women must have been amenorrheic for at least 12 months to be considered infertile), and their partners must voluntarily use effective contraception methods as deemed appropriate by the investigator during the treatment period and for at least 12 months after the last dose of the study drug.